ArticleEJNMMI research2026
Repeatability of tumour perfusion measurement with [
Article in EJNMMI research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- First-in-human quantitative [¹⁵O]H₂O PET imaging of tumour blood flow at rest and during exercise in lymphoma patients.Acta oncologica (Stockholm, Sweden) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundTumour perfusion is a universal cancer biomarker with potential value in characterising primary prostate tumours and longitudinal measurements for evaluation of treatment response. To evaluate whether a change in perfusion is significant, the reproducibility of the measurement must be known. [15O]H2O positron emission tomography (PET) is the gold standard for non-invasive quantitative perfusion imaging, however repeatability data on prostate cancer are currently unavailable. Hence, the aim of the present study is to determine the repeatability of [15O]H2O tumour perfusion in prostate cancer.
resultsThirteen well-defined MRI PI-RADS lesions from ten patients were studied. The repeatability of [15O]H2O K1 was 30% using both parametric image calculation and volume of interest (VOI)-based analysis. Intraclass correlation coefficient (ICC) was 0.89 and 0.91 for parametric image calculation and VOI-based analysis, respectively. A study sample size of 10 patients should be sufficient for detecting a relative change of 20% over time.
conclusions[15O]H2O tumour perfusion in localised prostate cancer can be measured with a high repeatability, showing comparable performance when using parametric K1 perfusion maps and VOI-based analysis. For longitudinal evaluation, changes above 30% are likely to represent actual changes in tumour perfusion, for example as response to a specific treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.